Phase II Clinical Trial

Title Average Ratingsort ascending
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate c 100.00%
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study. 100.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-s 100.00%
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal 100.00%
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable m 100.00%
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression 100.00%
Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. 95.00%
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) ...... 95.00%
Hibiscus sabdariffa L. Tea (Tisane) Lowers Blood Pressure in Prehypertensive and Mildly Hypertensive Adults 90.00%
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... 90.00%
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic soli 90.00%
Metronomic schedule of temozolomide with conventional dose of cisplatin in metastatic melanoma. Sub-category: Melanoma Categor 90.00%
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone mela 90.00%
Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? .. 90.00%
Cyclophosphamide plus somatostatin, bromocriptin, retinoids, melatonin and ACTH in the treatment of low-grade non-Hodgkin's .... 90.00%
The PEP-C regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. 90.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: 90.00%
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. 90.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced esoph 90.00%
Low-dose naltrexone therapy improves active Crohn's disease. 90.00%
Low-dose naltrexone for the treatment of irritable bowel syndrome: a pilot study. 90.00%
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent 90.00%
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. 85.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Double-blind, placebo-controlled, randomised study of single dose effects of ADAPT-232 on cognitive functions. 80.00%
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m 80.00%
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a .. 80.00%
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. 80.00%
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled 80.00%
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. 80.00%
Clinical studies of Ukrain in terminal cancer patients (phase II) 80.00%
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to... 80.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high... 80.00%
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid 80.00%
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ 80.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. 80.00%
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthe.... 80.00%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 80.00%
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glio 80.00%
Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen 80.00%
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in--- 80.00%
Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGN 80.00%
Low-Dose Naltrexone Therapy Improves Active Crohn’s Disease 80.00%
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. 80.00%
The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. 75.00%
Impressive survival data with semimetronomic oral chemotherapy with old agents in heavily treated metastatic breast cancer..... 75.00%
Effect of metronomic use of zoledronic acid (ZOL) on antitumor and antiosteoclastic effects in breast cancer patients with bone 70.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu 70.00%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r 70.00%
Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory....... 70.00%
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. 70.00%
Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for NSCLC. 70.00%
Local ultrasound hyperthermia as a component of radiotherapy for osteogenic sarcoma of tubular bones in children and adolescents 70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot 70.00%
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. 70.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer 70.00%
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma. 70.00%
Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119 70.00%
Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer. 70.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli 70.00%
Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer...... 60.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. 60.00%
Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. 60.00%
Pycnogenol may alleviate adverse effects in oncologic treatment. 60.00%
Ukrain both as an anti cancer and immunoregulatory agent 60.00%
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. 60.00%
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... 60.00%
The effects of thiophosphoric acid (Ukrain) on cervical cancer, stage IB bulky 60.00%
Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. 60.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Removed from Pubmed because of suspicion of scientific fraud: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). 55.00%
Alert because of Scientific Fraud: Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). 55.00%
Lymphocyte subsets in patients with lung cancer treated with thiophosphoric acid 55.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas ... 50.00%
Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. 50.00%
MET in small cell lung carcinoma (SCLC): Effects of a MET inhibitor in SCLC cell lines and prognostic role of MET status in pati 50.00%
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 50.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. 40.00%
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients .... 40.00%
Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer. 40.00%
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic 40.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer. 40.00%
One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma 40.00%
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. 40.00%
Ifosfamide, carboplatin, and etoposide (ICE) in combination with regional hyperthermia (RHT) in chemotherapy-pretreated non..... 40.00%